JP2013518130A5 - - Google Patents

Download PDF

Info

Publication number
JP2013518130A5
JP2013518130A5 JP2012551333A JP2012551333A JP2013518130A5 JP 2013518130 A5 JP2013518130 A5 JP 2013518130A5 JP 2012551333 A JP2012551333 A JP 2012551333A JP 2012551333 A JP2012551333 A JP 2012551333A JP 2013518130 A5 JP2013518130 A5 JP 2013518130A5
Authority
JP
Japan
Prior art keywords
bendamustine
long
term storage
containing composition
aqueous liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012551333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013518130A (ja
JP5795600B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/022958 external-priority patent/WO2011094565A1/en
Publication of JP2013518130A publication Critical patent/JP2013518130A/ja
Publication of JP2013518130A5 publication Critical patent/JP2013518130A5/ja
Application granted granted Critical
Publication of JP5795600B2 publication Critical patent/JP5795600B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012551333A 2010-01-28 2011-01-28 ベンダムスチンの製剤 Active JP5795600B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29910010P 2010-01-28 2010-01-28
US61/299,100 2010-01-28
PCT/US2011/022958 WO2011094565A1 (en) 2010-01-28 2011-01-28 Formulations of bendamustine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015160351A Division JP6133943B2 (ja) 2010-01-28 2015-08-17 ベンダムスチンの製剤

Publications (3)

Publication Number Publication Date
JP2013518130A JP2013518130A (ja) 2013-05-20
JP2013518130A5 true JP2013518130A5 (https=) 2014-03-13
JP5795600B2 JP5795600B2 (ja) 2015-10-14

Family

ID=44309429

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012551333A Active JP5795600B2 (ja) 2010-01-28 2011-01-28 ベンダムスチンの製剤
JP2015160351A Active JP6133943B2 (ja) 2010-01-28 2015-08-17 ベンダムスチンの製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015160351A Active JP6133943B2 (ja) 2010-01-28 2015-08-17 ベンダムスチンの製剤

Country Status (16)

Country Link
US (17) US8609707B2 (https=)
EP (3) EP3158991B1 (https=)
JP (2) JP5795600B2 (https=)
CA (1) CA2787568C (https=)
CY (2) CY1118769T1 (https=)
DK (2) DK3158991T3 (https=)
ES (2) ES2609106T5 (https=)
HR (2) HRP20161771T4 (https=)
HU (2) HUE031208T2 (https=)
LT (2) LT3158991T (https=)
PL (2) PL3158991T3 (https=)
PT (2) PT3158991T (https=)
RS (2) RS62327B1 (https=)
SI (2) SI3158991T1 (https=)
SM (3) SMT201700043T1 (https=)
WO (1) WO2011094565A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201700043T1 (it) 2010-01-28 2017-03-08 Eagle Pharmaceuticals Inc Formulazioni di bendamustina
MX363465B (es) 2011-02-18 2019-03-25 Kythera Biopharmaceuticals Inc Tratamiento de la grasa submental.
EP2806872A4 (en) * 2012-01-24 2014-12-03 Innopharma Inc BENDAMUSTIN COMPOSITIONS AND RELATED METHODS
JP2015506989A (ja) * 2012-02-14 2015-03-05 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチン製剤
JP6250628B2 (ja) * 2012-03-20 2017-12-20 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチンの製剤
CN104271135B (zh) * 2012-03-20 2017-05-17 赛多斯有限责任公司 在要求减少施用容量的患者中治疗苯达莫司汀响应性状况的方法
EP3043648B1 (en) 2013-08-27 2023-09-20 Vasilios VOUDOURIS Bendamustine pharmaceutical compositions
KR20160060656A (ko) * 2013-09-20 2016-05-30 산텐 세이야꾸 가부시키가이샤 폴리에틸렌글리콜 함유 조성물
US20160235717A1 (en) * 2013-10-11 2016-08-18 Luitpold Pharmaceuticals, Inc. Bendamustine pharmaceutical compositions
EP3116481A1 (en) * 2014-03-13 2017-01-18 Vasilios VOUDOURIS Bendamustine solid dispersions and continuous infusion
WO2016005995A2 (en) * 2014-07-10 2016-01-14 Leiutis Pharmaceuticals Pvt. Ltd. Glycol free stable liquid compositions of bendamustine
US9603930B2 (en) 2014-12-04 2017-03-28 Navinta, Llc Liquid bendamustine formulation
JP2018532806A (ja) * 2015-11-04 2018-11-08 キセラ バイオファーマシューティカルズ インコーポレイテッド デオキシコール酸およびその塩による蓄積脂肪の処置方法
US10905677B2 (en) 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations
US11826466B2 (en) 2016-08-31 2023-11-28 Navinta, Llc Bendamustine solution formulations
EP3773498B1 (en) 2018-03-29 2022-06-22 Project Pharmaceutics GmbH Liquid pharmaceutical formulation
EP3836921B1 (en) 2018-08-17 2025-10-08 Hospira Australia Pty Ltd Liquid bendamustine pharmaceutical compositions
US11730815B2 (en) 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
JP2020090481A (ja) * 2018-11-27 2020-06-11 日本化薬株式会社 ベンダムスチンを含有する溶液製剤
JP7235288B2 (ja) * 2019-01-07 2023-03-08 コーアイセイ株式会社 ベンダムスチンの液体製剤
WO2020170104A1 (en) * 2019-02-18 2020-08-27 Shilpa Medicare Limited Liquid bendamustine parenteral compositions
WO2021161876A1 (ja) * 2020-02-10 2021-08-19 富士フイルム株式会社 ベンダムスチン液剤
JP2023529033A (ja) * 2020-04-09 2023-07-07 ビカ・バイオテック(グアンジョウ)・カンパニー・リミテッド ベンダムスチン組成物及びその用途
JP2024537431A (ja) 2021-10-22 2024-10-10 プロジェクト ファーマシューティクス ゲーエムベーハー 液状薬学的製剤
GB202118175D0 (en) 2021-12-15 2022-01-26 Arecor Ltd Novel composition
US11707450B1 (en) * 2022-03-03 2023-07-25 Slayback Pharma Llc Stable pharmaceutical compositions of bendamustine

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE80967C (https=)
DE159289C (https=) * 1903-10-08 1905-03-16
DE152989C (https=)
US4071620A (en) 1977-01-10 1978-01-31 American Home Products Corporation Stabilization of oxygen sensitive dose forms
DD152989A1 (de) 1980-09-11 1981-12-16 Klaus Kunze Anordnung zur korrektur von soll-und istwerten
DD159289A1 (de) * 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DE3446873A1 (de) * 1984-12-21 1986-07-10 Merckle Gmbh Fluessige diclofenac-zubereitungen
US5204335A (en) 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US4879286A (en) 1987-01-28 1989-11-07 Lyphomed, Inc. Cyclophosphamide
US5223515A (en) 1988-08-18 1993-06-29 Takeda Chemical Industries, Ltd. Injectable solution containing a pyridyl methylsulfinylbenzimidazole
DK0725642T3 (da) 1993-10-27 2000-05-29 Upjohn Co Stabiliseret prostaglandin E1
MX9602955A (es) 1994-01-24 1997-06-28 Procter & Gamble Procedimiento para solubizar activos farmaceuticos dificilmente solubles.
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
WO1999001118A2 (en) 1997-07-01 1999-01-14 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
WO1999053918A1 (en) * 1998-04-20 1999-10-28 Eisai Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6686365B2 (en) * 2000-02-04 2004-02-03 Eli Lilly And Company Pharmaceutical composition
US6989139B2 (en) 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
JP2005538030A (ja) 2000-06-21 2005-12-15 デュポン ファーマシューティカルズ カンパニー 組み合わせ療法での使用のための血管新生障害の画像診断用医薬
AU2001271435A1 (en) 2000-06-21 2002-01-02 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2413957A1 (en) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
AUPQ849900A0 (en) 2000-06-30 2000-07-27 Dbl Australia Pty Ltd. Injectable composition
CA2413538A1 (en) 2000-07-06 2002-01-17 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions and methods for preparation thereof
WO2002032427A1 (en) * 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
US7252799B2 (en) * 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
AR040693A1 (es) * 2002-07-30 2005-04-13 Wyeth Corp Formulaciones parenterales
US20060035945A1 (en) 2003-05-30 2006-02-16 Giorgio Attardo Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
US20060001597A1 (en) 2004-06-30 2006-01-05 Sokbom Han Image processing apparatus, systems and associated methods
MX2007005361A (es) 2004-11-05 2008-01-11 Cephalon Inc Tratamientos para cancer.
PT1814517E (pt) 2004-11-22 2010-11-03 Venus Remedies Ltd Formulação parentérica líquida não aquosa de aceclofenac
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US20080200383A1 (en) 2005-04-08 2008-08-21 Amylin Pharmaceuticals, Inc. Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN1850048A (zh) 2006-06-09 2006-10-25 山东蓝金生物工程有限公司 一种含血管抑制剂的抗癌缓释注射剂
WO2008020584A1 (en) 2006-08-14 2008-02-21 Eisai R & D Management Co., Ltd. Stable lyophilized preparation
EP2073802A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
DE102007003184A1 (de) 2007-01-22 2008-07-24 Orlowski, Michael, Dr. Verfahren zur Beladung von strukturierten Oberflächen
US20090082416A1 (en) 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched bendamustine
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CA2735899A1 (en) 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
US8076366B2 (en) 2009-01-15 2011-12-13 Cephalon, Inc. Forms of bendamustine free base
ES2525257T3 (es) 2009-02-25 2014-12-19 Supratek Pharma, Inc. Composiciones de ciclopolisacárido y de bendamustina
WO2010114770A1 (en) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
US20100273730A1 (en) 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
JP2012525387A (ja) * 2009-04-28 2012-10-22 セファロン、インク. ベンダムスチンの経口製剤
CN101584668A (zh) 2009-06-19 2009-11-25 江苏奥赛康药业有限公司 盐酸苯达莫司汀冻干粉针剂
WO2010148288A2 (en) 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
US20110015245A1 (en) 2009-07-20 2011-01-20 Valery Alakhov Bendamustine amphiphilic cationic compositions
US8389558B2 (en) 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
US7772274B1 (en) * 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
SMT201700043T1 (it) 2010-01-28 2017-03-08 Eagle Pharmaceuticals Inc Formulazioni di bendamustina
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013540104A (ja) 2010-07-28 2013-10-31 イーグル・ファーマシューティカルズ・インコーポレーテッド 延長された保存安定性を有するペメトレキセドを含有する医薬組成物
EP2635558A4 (en) 2010-11-01 2014-08-06 Shilpa Medicare Ltd PROCESS FOR PREPARING BENDAMUSTINE HYDROCHLORIDE MONOHYDRATE
JP2014516075A (ja) 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
CA2857177C (en) 2011-12-05 2020-06-23 Bio-Rad Laboratories, Inc. Recombinant deamidated gliadin antigen
AU2012347972B2 (en) 2011-12-05 2018-05-10 X-Body, Inc. PDGF receptor beta binding polypeptides
EP2806872A4 (en) 2012-01-24 2014-12-03 Innopharma Inc BENDAMUSTIN COMPOSITIONS AND RELATED METHODS
JP2015506989A (ja) 2012-02-14 2015-03-05 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチン製剤
JP6250628B2 (ja) 2012-03-20 2017-12-20 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチンの製剤
CN104271135B (zh) 2012-03-20 2017-05-17 赛多斯有限责任公司 在要求减少施用容量的患者中治疗苯达莫司汀响应性状况的方法
JP6331468B2 (ja) 2014-02-27 2018-05-30 住友ベークライト株式会社 金属ラミネート用フィルム、ラミネート金属板および金属容器
US11707450B1 (en) * 2022-03-03 2023-07-25 Slayback Pharma Llc Stable pharmaceutical compositions of bendamustine

Similar Documents

Publication Publication Date Title
JP2013518130A5 (https=)
HRP20161771T4 (hr) Formulacije bendamustina
JP2015506989A5 (https=)
ES2656901T3 (es) Una formulación estabilizada de pemetrexed
RU2016119746A (ru) Стабильный состав инсулина глулизин
WO2012015810A3 (en) Pharmaceutical compositions containing pemetrexed having extended storage stability
CY1122516T1 (el) Ετοιμες προς χρηση διατυπωσεις κετορολακης
JP2010265321A5 (https=)
JP2015527402A5 (https=)
BR112014009146A2 (pt) formulações de etanercepte estabilizadas com aminoácidos
RU2019118696A (ru) Фармацевтические композиции, содержащие инсулин
BR112015008186A2 (pt) formulação de um anticorpo estável e de baixa viscosidade
CO6311066A2 (es) Composiciones de alta densidad que contienen posaconazol y formulaciones que comprenden las mismas
EA201290128A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
AR095456A1 (es) Composiciones de dos componentes que contienen complejos de halogenuro de cinc y aminoácido y cisteína
UA109281C2 (uk) Фармацевтична композиція, яка містить похідне аміду або його фармацевтично прийнятну сіль
RU2016147362A (ru) Препараты жидкого концетрата циклофосфамида
JP2017514924A5 (https=)
MX2017010945A (es) Preparacion solida.
MX362807B (es) Formulacion estabilizada de pemetrexed.
JP2015514120A5 (https=)
ECSP12011699A (es) Tableta
MX2017016862A (es) Composicion farmaceutica estable para administracion oral.
MX2014014609A (es) Composicion para prevenir dolores de cabeza.
EA201170287A1 (ru) Фармацевтические композиции и способы их стабилизации